mLogica Acquires Innovative Legacy Modernization Firm Reverse Paradigm, Augmenting Their Recent Acquisition of the LIBER Software Suite from Atos
mLogica, a global provider of database, mainframe and application modernization services, today announced it’s releasing the most comprehensive set of tools on the market for mainframe migration to the cloud. It’s a move made possible by their recent acquisition of pioneering Italian mainframe technology firm Reverse Paradigm, as well as several other strategic purchases of key technology players and assets earlier this year.
This follows mLogica’s recent acquisition of the groundbreaking LIBER software suite from French multinational information technology firm Atos. The LIBER tool set lets firms with outdated mainframe applications gain the flexibility, scalability and adaptability only possible in the cloud—while retaining all the stability and functionality of their existing systems.
Longtime experts in database and application modernization to the cloud, with these acquisitions mLogica now offers the most complete migration tool set for both private and public sector organizations that can no longer delay updating their antiquated IT systems. The combined toolset will now be marketed as the LIBER*M Mainframe Modernization Suite.
Says mLogica president and CEO Amit Okhandiar, “One of the most important considerations when approaching a complex project like legacy system modernization is the impact it could have on your business’s day-to-day operations. The more moving parts, the more time-consuming, error-prone and logistically challenging it becomes.”
Okhandiar feels simplifying the modernization process is key for customer success. “With these purchases of Reverse Paradigm and the LIBER suite, mLogica is now the one firm that can provide end-to-end expertise, tools and support for every phase of modernization to the cloud. We streamline the entire process so our clients, and their IT staff, can focus on their daily business—knowing they can trust us to deliver on-time, on-budget and with complete accuracy and security.”
mLogica Senior VP of Solution Architecture and Global Operations, Anthony Veltri concurs, “The most exciting aspect of this purchase is that the tools we’ve acquired can be leveraged when we collaborate on projects with our long-standing partners in mainframe migration and system integration, as well as with global cloud providers.”
“These new acquisitions significantly advance our mission to provide our clients with the most comprehensive set of tools on the market, plus expert service and support, which allows them to dramatically reduce the timeline, risks and cost of modernizing workloads of all sizes.”
Reverse Paradigm’s founder and president, Santino Spagnoli, who will now become mLogica’s VP of Engineering for Mainframe Modernization, feels the move points the way to the future of information technology. “We’re excited to become part of a solution-focused organization, which allows us to provide even greater support to our migration partners—and accelerate innovation for the mainframe modernization market.”
About mLogica
mLogica’s mission is to help drive enterprise efficiency through cloud migration. Founded by professionals from leading technology companies, mLogica specializes in migrating complex, legacy on-premise business applications and databases, both mainframe and distributed, to the cloud.
mLogica leverages its automated distributed systems modernization software suite STAR*M , and their mainframe modernization software, LIBER*M , to migrate legacy systems to the cloud. mLogica also modernizes big data applications with their hyperscale petabyte+ big data software CAP*M , and their software-driven TRAK*M managed services programs.
For more information, visit https://www.mLogica.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005338/en/
Contact information
For mLogica:
Michael Kane
+1 (917) 544 6019
michael.kane@mLogica.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom